Qiagen (NYSE:QGEN - Get Free Report) is projected to post its quarterly earnings results after the market closes on Wednesday, February 5th. Analysts expect Qiagen to post earnings of $0.60 per share and revenue of $518.54 million for the quarter. Parties that wish to listen to the company's conference call can do so using this link.
Qiagen Price Performance
Shares of QGEN traded down $2.63 during mid-day trading on Wednesday, reaching $43.81. 1,042,042 shares of the company's stock were exchanged, compared to its average volume of 1,163,032. The company has a quick ratio of 1.89, a current ratio of 2.17 and a debt-to-equity ratio of 0.39. Qiagen has a 52-week low of $40.15 and a 52-week high of $49.30. The company has a market cap of $10.00 billion, a price-to-earnings ratio of 112.32, a PEG ratio of 3.49 and a beta of 0.37. The company has a 50-day simple moving average of $44.81 and a two-hundred day simple moving average of $44.37.
Analyst Upgrades and Downgrades
A number of research firms have recently weighed in on QGEN. Jefferies Financial Group reissued a "buy" rating and issued a $54.00 price target (up from $42.00) on shares of Qiagen in a report on Tuesday, December 10th. Morgan Stanley restated an "equal weight" rating and issued a $48.00 target price (down from $50.00) on shares of Qiagen in a report on Monday, January 6th. HSBC downgraded shares of Qiagen from a "buy" rating to a "hold" rating and set a $49.00 price target for the company. in a report on Thursday, October 17th. Finally, Hsbc Global Res raised shares of Qiagen to a "hold" rating in a research note on Thursday, October 17th. Four investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $51.50.
View Our Latest Stock Report on Qiagen
About Qiagen
(
Get Free Report)
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.
Further Reading
Before you consider Qiagen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Qiagen wasn't on the list.
While Qiagen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
